PMID- 20299238
OWN - NLM
STAT- MEDLINE
DCOM- 20100616
LR  - 20181201
IS  - 1096-0023 (Electronic)
IS  - 1043-4666 (Linking)
VI  - 50
IP  - 2
DP  - 2010 May
TI  - Monocyte chemoattractant protein-1: a dichotomous role in cardiac remodeling 
      following acute myocardial infarction in man?
PG  - 158-62
LID - 10.1016/j.cyto.2010.02.020 [doi]
AB  - INTRODUCTION: Monocyte chemoattractant protein-1 (MCP-1) is elevated after acute 
      myocardial infarction (AMI), and potentiates left ventricular (LV) remodeling in 
      murine models of AMI. We examined the relationships between serum MCP-1, change 
      in LV function and biomarkers related to remodeling in a cohort of AMI patients. 
      METHODS: Serum MCP-1 concentrations were measured in 100 patients (age 
      58.9+/-12.0 years, 77% male) admitted with AMI and LV dysfunction, at baseline 
      (mean 46 h), 12 and 24 weeks; cardiac magnetic resonance imaging and measurement 
      of matrix metalloproteinase-2 (MMP-2), MMP-3 and MMP-9 occurred at each 
      time-point. RESULTS: MCP-1 increased significantly from 697 [483, 997]pg/mL at 
      baseline to 878 [678, 1130]pg/mL at 24 weeks (p<0.001). MMP-3 concentration 
      increased while MMP-9 decreased significantly over time; MMP-2 concentration did 
      not change significantly. BASELINE MCP-1 correlated with change in (Delta) LV 
      end-systolic volume index (DeltaLVESVI; r= -0.48, p=0.01) and with DeltaLV 
      ejection fraction (DeltaLVEF; r=0.50, p=0.02). However, DeltaMCP-1 correlated 
      positively with DeltaLVESVI (r=0.40, p=0.006) and negatively with DeltaLVEF (r= 
      -0.36, p=0.004). MCP-1 had no relationship with any MMP. CONCLUSIONS: MCP-1 may 
      have a dichotomous role following AMI, aiding early infarct healing but 
      potentiating later remodeling, which merits further study before any therapeutic 
      trials of MCP-1 modulation in humans.
CI  - Copyright (c) 2010 Elsevier Ltd. All rights reserved.
FAU - Weir, Robin A P
AU  - Weir RA
AD  - Cardiology Department, Western Infirmary, Glasgow, Scotland, UK. 
      robinweir75@hotmail.com
FAU - Murphy, Charles Aengus
AU  - Murphy CA
FAU - Petrie, Colin J
AU  - Petrie CJ
FAU - Martin, Thomas N
AU  - Martin TN
FAU - Clements, Suzanne
AU  - Clements S
FAU - Steedman, Tracey
AU  - Steedman T
FAU - Wagner, Galen S
AU  - Wagner GS
FAU - McMurray, John J V
AU  - McMurray JJ
FAU - Dargie, Henry J
AU  - Dargie HJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100317
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Contrast Media)
RN  - 0 (Mineralocorticoid Receptor Antagonists)
RN  - 27O7W4T232 (Spironolactone)
RN  - 6995V82D0B (Eplerenone)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Biomarkers/blood
MH  - Chemokine CCL2/*blood
MH  - Cohort Studies
MH  - Contrast Media
MH  - Eplerenone
MH  - Female
MH  - Humans
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Matrix Metalloproteinases/metabolism
MH  - Middle Aged
MH  - Mineralocorticoid Receptor Antagonists/therapeutic use
MH  - Myocardial Infarction/*blood/drug therapy/enzymology/*physiopathology
MH  - Spironolactone/analogs & derivatives/therapeutic use
MH  - Time Factors
MH  - Ventricular Function, Left/physiology
MH  - Ventricular Remodeling/*physiology
EDAT- 2010/03/20 06:00
MHDA- 2010/06/17 06:00
CRDT- 2010/03/20 06:00
PHST- 2009/10/01 00:00 [received]
PHST- 2009/11/25 00:00 [revised]
PHST- 2010/02/28 00:00 [accepted]
PHST- 2010/03/20 06:00 [entrez]
PHST- 2010/03/20 06:00 [pubmed]
PHST- 2010/06/17 06:00 [medline]
AID - S1043-4666(10)00059-1 [pii]
AID - 10.1016/j.cyto.2010.02.020 [doi]
PST - ppublish
SO  - Cytokine. 2010 May;50(2):158-62. doi: 10.1016/j.cyto.2010.02.020. Epub 2010 Mar 
      17.